‘We’re not finished with remdesivir’: Gilead CEO says trials underway for inhaled version, outpatient IV version

” If one could do it without an IV, right to the website of where you get this duplication of the virus in the lungs, were also confident that you may be able to deal with outside the hospital and prevent patients from ever going to the hospital,” Mr. ODay informed CNBC.

Katie Adams –
Tuesday, September 15th, 2020
Print|Email.

More articles on pharmacy: Gilead expands oncology portfolio, gets Immunomedics for $21BNIH screening blood slimmers as COVID-19 treatment8 considerations to take when preparing for COVID-19 vaccine distribution.

The FDA provided an emergency situation use authorization for remdesivir as a COVID-19 treatment May 1, stipulating that the drug just be utilized to treat hospitalized COVID-19 clients who are using ventilators or have low blood oxygen levels. On Aug. 28, the company expanded remdesivirs emergency use authorization to permit all hospitalized COVID-19 patients, despite case severity, to be treated with the antiviral drug.

” Were not ended up with remdesivir,” Mr. ODay informed CNBC.

Mr. ODay stated Gilead started scientific trials checking out intravenous remdesivir in outpatient settings in September..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Gilead is studying new methods to use remdesivir as a COVID-19 treatment, CEO Daniel ODay stated Sept. 14 during a CNBC interview.

He also disclosed the drugmaker started evaluating the drug in an inhaled form in July.